ASTRAZEN — Astrazeneca Pharma India Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Astrazeneca Pharma India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,056	10,030	12,955	17,163	22,756
Cost of Revenue
Gross Profit	4,400	5,722	6,174	7,104	8,950
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	7,362	8,943	11,089	15,987	20,474
Operating Profit	694	1,086	1,866	1,176	2,282
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	830	1,341	2,195	1,564	2,522
Provision for Income Taxes
Net Income After Taxes	616	993	1,615	1,157	1,875
Net Income Before Extraordinary Items
Net Income	616	993	1,615	1,157	1,875
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	616	993	1,615	1,157	1,875
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	23.8	50.9	60.1	75	76.6
Dividends per Share